# BreezeBio

> BreezeBio (formerly GenEdit) is a Brisbane, California-based biotechnology company that develops precision genetic medicines using its proprietary NanoGalaxy platform - a library of polymer nanoparticles capable of delivering genetic payloads like mRNA, siRNA, and CRISPR components to specific tissues without triggering immune responses. Unlike viral vectors that can only be dosed once and often provoke dangerous immune reactions, BreezeBio's non-viral approach allows repeat dosing, broad payload flexibility, and tissue selectivity across immune cells, heart, lung, and CNS. Founded in 2016 out of UC Berkeley by CEO Dr. Kunwoo Lee and CTO Dr. Hyo Min Park, the company rebranded from GenEdit in early 2026 following its $60M Series B, signaling a shift from delivery-platform licensor to full therapeutic developer with a lead program (BRZ-101) targeting Type 1 Diabetes.

- **Founded:** 2016
- **Headquarters:** Brisbane, California, United States
- **Founders:** Dr. Kunwoo Lee (CEO & Co-Founder), Dr. Hyo Min Park (CTO & Co-Founder)
- **Team size:** ~64 employees
- **Products:** NanoGalaxy Platform, BRZ-101, Partnership Discovery Engine
- **Notable:** Rebranded from GenEdit to BreezeBio in February 2026 alongside $60M Series B, Achieved first milestone in $644M Roche/Genentech collaboration (May 2025), NIH TARGETED Challenge Phase I winner (December 2023) for programmable gene editing delivery

## Products & services

- **NanoGalaxy Platform** — A combinatorial library of hydrophilic polymer nanoparticles engineered for tissue-selective delivery of genetic payloads including mRNA, siRNA, ASOs, therapeutic proteins, and CRISPR components. Key advantages: no innate immune activation, re-dosability, and demonstrated delivery to immune cells, heart, lung, and CNS.
- **BRZ-101** — Lead internal therapeutic program targeting Type 1 Diabetes. Delivers autoantigens encoded by mRNA plus tolerogenic co-factors to antigen-presenting cells, inducing antigen-specific regulatory T cells (Tregs) to restore immune tolerance. Advancing toward IND-enabling studies.
- **Partnership Discovery Engine** — Custom nanoparticle discovery and optimization services for pharmaceutical partners seeking to deliver specific nucleic acid payloads to defined tissues. Active collaborations with Roche/Genentech (autoimmune) and Sarepta Therapeutics (neuromuscular diseases).

## Achievements

- Rebranded from GenEdit to BreezeBio in February 2026 alongside $60M Series B
- Achieved first milestone in $644M Roche/Genentech collaboration (May 2025)
- NIH TARGETED Challenge Phase I winner (December 2023) for programmable gene editing delivery
- Forbes 30 Under 30 recognition for CEO Dr. Kunwoo Lee (2017)
- Dr. Kunwoo Lee named Siebel Scholar (2016)
- Total funding of $118.5M raised since founding
- Demonstrated NanoGalaxy delivery to four distinct tissue types: immune cells, heart, lung, CNS
- BRZ-101 showed efficacy in NOD mouse model of Type 1 Diabetes and was well tolerated in non-human primates

## Latest updates

- **2026-02** — Raised $60M Series B and rebranded from GenEdit to BreezeBio, signaling pivot to internal therapeutic pipeline
- **2025-05** — Achieved first milestone in up to $644M Roche/Genentech nanoparticle collaboration for autoimmune diseases
- **2024-01** — Secured $24M Series A1 led by Eli Lilly to advance NanoGalaxy platform and pipeline
- **2023-12** — Won NIH TARGETED Challenge Phase I for programmable gene editing delivery systems
- **2022-02** — Announced $57M partnership with Sarepta Therapeutics for neuromuscular gene editing therapeutics
- **2021-09** — Raised $26M Series A with Eli Lilly joining as strategic investor alongside DCVC Bio and Sequoia Capital

## Links

- Website: https://breezebio.com
- LinkedIn: https://www.linkedin.com/company/breezebio
- Twitter/X: https://twitter.com/genedit_inc

---

Profile page: https://yespress.io/breezebio
Published by YesPress — https://yespress.io
Last updated: 2026-05-19